{"id":3066,"date":"2023-06-23T07:05:00","date_gmt":"2023-06-23T07:05:00","guid":{"rendered":"https:\/\/capilart.pt\/la-fda-aprueba-litfulo-ritlecitinib-para-adultos-y-adolescentes-con-alopecia-areata-grave\/"},"modified":"2023-09-28T10:35:53","modified_gmt":"2023-09-28T10:35:53","slug":"la-fda-aprueba-litfulo-ritlecitinib-para-adultos-y-adolescentes-con-alopecia-areata-grave","status":"publish","type":"post","link":"https:\/\/capilart.pt\/es\/la-fda-aprueba-litfulo-ritlecitinib-para-adultos-y-adolescentes-con-alopecia-areata-grave\/","title":{"rendered":"La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"3066\" class=\"elementor elementor-3066\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<footer class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-92a6661 elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"92a6661\" data-element_type=\"section\">\r\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-thegem\"><div class=\"elementor-row\">\r\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-c32a5b2 jltma-glass-effect-no\" data-id=\"c32a5b2\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-708c35f flex-horizontal-align-default flex-horizontal-align-tablet-default flex-horizontal-align-mobile-default flex-vertical-align-default flex-vertical-align-tablet-default flex-vertical-align-mobile-default jltma-glass-effect-no elementor-invisible elementor-widget elementor-widget-heading\" data-id=\"708c35f\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"default elementor-heading-title elementor-size-default\">La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e1fcae9 flex-horizontal-align-default flex-horizontal-align-tablet-default flex-horizontal-align-mobile-default flex-vertical-align-default flex-vertical-align-tablet-default flex-vertical-align-mobile-default jltma-glass-effect-no elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"e1fcae9\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"elementor-text-editor elementor-clearfix\">\r\n\t\t\t\t\t\t<p>Hoy, la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA) aprob\u00f3 LITFULO\u2122 para la alopecia areata grave, marcando el segundo tratamiento aprobado por la FDA para esta enfermedad y el primero aprobado para ni\u00f1os mayores de 12 a\u00f1os. \u00abLa Fundaci\u00f3n Nacional de Alopecia Areata est\u00e1 encantada de tener un segundo tratamiento aprobado por la FDA para la alopecia areata, el primero aprobado para adolescentes. Continuamos viendo resultados tangibles de los esfuerzos iniciales de nuestro Programa de Desarrollo de Tratamiento para sentar las bases cient\u00edficas para estos avances\u00bb, dijo Nicole Friedland, presidenta y directora ejecutiva de NAAF. \u00abSeguimos comprometidos a apoyar m\u00e1s descubrimientos y empoderar a nuestra comunidad con m\u00e1s opciones\u00bb. LITFULO\u2122 (ritlecitinib) pertenece a una clase de medicamentos conocidos como inhibidores de la cinasa janus (JAK). LITFULO\u2122 est\u00e1 aprobado por la FDA para adultos y ni\u00f1os mayores de 12 a\u00f1os con alopecia areata grave. LITFULO, fabricado por Pfizer Inc.,\u2122 est\u00e1 disponible solo con receta m\u00e9dica.<\/p>\n<p>La National Alopecia Areata Foundation (NAAF) apoya la investigaci\u00f3n para encontrar una cura o tratamiento aceptable para la alopecia areata, apoya a las personas con la enfermedad y educa al p\u00fablico sobre la alopecia areata. La alopecia areata es una enfermedad autoinmune com\u00fan que afecta a casi 7 millones de estadounidenses y resulta en la p\u00e9rdida total o parcial del cabello en el cuero cabelludo y el cuerpo. Fundada en 1981 y con sede en San Rafael, CA, NAAF es ampliamente reconocida como la organizaci\u00f3n de defensa de la alopecia areata m\u00e1s grande de los Estados Unidos. NAAF se conecta con la comunidad de alopecia areata, incluidos pacientes, familiares, profesionales de la salud e investigadores, a trav\u00e9s de sus programas de apoyo, boletines informativos por correo electr\u00f3nico, sitio web, cumbres de investigaci\u00f3n y conferencias anuales de pacientes. NAAF es una organizaci\u00f3n sin fines de lucro 501 (c) (3) y una organizaci\u00f3n ben\u00e9fica con calificaci\u00f3n Candid Platinum, que cumple con los rigurosos est\u00e1ndares de Better Business Bureau Wise Giving Alliance y el Consejo Nacional de Salud.<\/p>\n<p>Lea el comunicado de prensa de Pfizer <a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and\">aqu\u00ed<\/a>.<\/p>\n\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div><\/div>\r\n\t\t<\/footer>\r\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Hoy, la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 LITFULO\u2122 para la alopecia areata grave, marcando el segundo tratamiento aprobado por la FDA para esta enfermedad y el primero aprobado para ni\u00f1os mayores de 12 a\u00f1os.<\/p>\n","protected":false},"author":1,"featured_media":2562,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"single-fullwidth.php","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[56],"tags":[],"class_list":["post-3066","post","type-post","status-publish","format-standard","has-post-thumbnail","category-blog-es"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave - Capilart<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave - Capilart\" \/>\n<meta property=\"og:description\" content=\"Hoy, la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 LITFULO\u2122 para la alopecia areata grave, marcando el segundo tratamiento aprobado por la FDA para esta enfermedad y el primero aprobado para ni\u00f1os mayores de 12 a\u00f1os.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\" \/>\n<meta property=\"og:site_name\" content=\"Capilart\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-23T07:05:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-28T10:35:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"387\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Leo GT\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leo GT\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\",\"url\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\",\"name\":\"La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave - Capilart\",\"isPartOf\":{\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg\",\"datePublished\":\"2023-06-23T07:05:00+00:00\",\"dateModified\":\"2023-09-28T10:35:53+00:00\",\"author\":{\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/3d0be1ae22494c399605db2b1962ab46\"},\"breadcrumb\":{\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage\",\"url\":\"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg\",\"contentUrl\":\"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg\",\"width\":700,\"height\":387},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/capilart.pt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#website\",\"url\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/\",\"name\":\"Capilart\",\"description\":\"Especialistas em transplantes capilares\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/3d0be1ae22494c399605db2b1962ab46\",\"name\":\"Leo GT\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ec0fcf2df12a95709091aef430cdc31cb90f4f7d50db54af4bfbdb9c79396150?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ec0fcf2df12a95709091aef430cdc31cb90f4f7d50db54af4bfbdb9c79396150?s=96&d=mm&r=g\",\"caption\":\"Leo GT\"},\"sameAs\":[\"http:\/\/capilart.pt\"],\"url\":\"https:\/\/capilart.pt\/es\/author\/workforce\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave - Capilart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/","og_locale":"es_ES","og_type":"article","og_title":"La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave - Capilart","og_description":"Hoy, la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 LITFULO\u2122 para la alopecia areata grave, marcando el segundo tratamiento aprobado por la FDA para esta enfermedad y el primero aprobado para ni\u00f1os mayores de 12 a\u00f1os.","og_url":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/","og_site_name":"Capilart","article_published_time":"2023-06-23T07:05:00+00:00","article_modified_time":"2023-09-28T10:35:53+00:00","og_image":[{"width":700,"height":387,"url":"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg","type":"image\/jpeg"}],"author":"Leo GT","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Leo GT","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/","url":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/","name":"La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave - Capilart","isPartOf":{"@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage"},"image":{"@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage"},"thumbnailUrl":"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg","datePublished":"2023-06-23T07:05:00+00:00","dateModified":"2023-09-28T10:35:53+00:00","author":{"@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/3d0be1ae22494c399605db2b1962ab46"},"breadcrumb":{"@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage","url":"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg","contentUrl":"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg","width":700,"height":387},{"@type":"BreadcrumbList","@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/capilart.pt\/"},{"@type":"ListItem","position":2,"name":"La FDA aprueba LITFULO\u2122 (ritlecitinib) para adultos y adolescentes con alopecia areata grave"}]},{"@type":"WebSite","@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#website","url":"https:\/\/indigo-manatee-815528.hostingersite.com\/","name":"Capilart","description":"Especialistas em transplantes capilares","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/indigo-manatee-815528.hostingersite.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/3d0be1ae22494c399605db2b1962ab46","name":"Leo GT","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ec0fcf2df12a95709091aef430cdc31cb90f4f7d50db54af4bfbdb9c79396150?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ec0fcf2df12a95709091aef430cdc31cb90f4f7d50db54af4bfbdb9c79396150?s=96&d=mm&r=g","caption":"Leo GT"},"sameAs":["http:\/\/capilart.pt"],"url":"https:\/\/capilart.pt\/es\/author\/workforce\/"}]}},"menu_order":0,"_links":{"self":[{"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/posts\/3066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/comments?post=3066"}],"version-history":[{"count":1,"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/posts\/3066\/revisions"}],"predecessor-version":[{"id":3067,"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/posts\/3066\/revisions\/3067"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/media\/2562"}],"wp:attachment":[{"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/media?parent=3066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/categories?post=3066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/capilart.pt\/es\/wp-json\/wp\/v2\/tags?post=3066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}